NCI Center for Cancer Research (intramural programme)
The NCI's own laboratories and clinic at the NIH Clinical Center, home of Rosenberg's cell therapy branch, the HPV vaccine and lymphoma genomics.
The Center for Cancer Research is the NCI's intramural research programme, with laboratories in Bethesda and Frederick and a clinical arm at the NIH Clinical Center, the largest hospital in the world devoted to research, where patients on protocol are treated free of charge. Steven Rosenberg's Surgery Branch produced the first effective cancer immunotherapy (high-dose IL-2), the first gene-modified T cells (1990), TIL therapy and neoantigen-directed TCR therapy; Douglas Lowy and John Schiller invented the virus-like-particle technology behind HPV vaccines; Louis Staudt's lymphoma genomics defined the ABC and GCB subtypes of DLBCL. The Pediatric Oncology Branch (Brigitte Widemann, Nirali Shah) led selumetinib for NF1 and CD22 CAR-T, and James Gulley and Raffit Hassan run immunotherapy and mesothelin programmes. Most CCR trials are open to referral from any physician.
- Surgery Branch (TIL, TCR-T)
- HPV vaccine science
- Lymphoid malignancies
- Pediatric Oncology Branch
- NIH Clinical Center trials
Father of cancer immunotherapy: first to cure patients with IL-2 and with their own tumour-infiltrating lymphocytes.
Louis Staudt defined the molecular subtypes of large B-cell lymphoma that guide targeted therapy.
Co-developed the HPV vaccine technology that is eliminating cervical cancer in vaccinated populations.
Runs NCI's immuno-oncology clinical programme, from prostate cancer vaccines to bifunctional checkpoint fusion proteins.
Led the selumetinib trials that gave children with neurofibromatosis their first approved drug.
Nirali Shah developed CD22 CAR-T for children whose leukaemia escaped CD19 therapy.
Made mesothelin a drug target, from immunotoxins to ADCs and CAR-T, and leads NCI's mesothelioma programme.
Pages like this
not linked directly; found by shared links- Key paperC-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed
Shares Aldesleukin (high-dose IL-2), Steven A. Rosenberg, TIL therapy, National Cancer Institute (NIH).
- PersonPhilip D. Greenberg
Shares Mesothelin, TCR-T cell therapy, CAR-T cell therapy.
- IdeaRegionally delivered mesothelin CAR-T with PD-1 blockade
Shares Mesothelin, Mesothelioma, CAR-T cell therapy.
- InstitutionTongji Hospital, Huazhong University of Science and Technology
Shares HPV & HBV vaccination, Cervical cancer, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- InstitutionUganda Cancer Institute
Shares HPV & HBV vaccination, National Cancer Institute (NIH), Cervical cancer, Diffuse large B-cell lymphoma.
- IdeaPublic cell-therapy foundries at cancer centres for academics and start-ups
Shares TIL therapy, TCR-T cell therapy, CAR-T cell therapy.
- PersonIan Frazer
Shares Douglas R. Lowy, HPV & HBV vaccination, Cervical cancer.
- PersonPatrick Hwu
Shares TIL therapy, TCR-T cell therapy, Melanoma.